This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the activity for this article:
 Basic Science Test 4: Recent Topics in Basic Science
Right arrow [Supplementary Material]
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seeherman, H. J.
Right arrow Articles by Wozney, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seeherman, H. J.
Right arrow Articles by Wozney, J. M.
Related Collections
Right arrow Basic Science
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Facebook   Add to Technorati   Add to Twitter  
What's this?
The Journal of Bone and Joint Surgery (American) 86:1961-1972 (2004)
© 2004 The Journal of Bone and Joint Surgery, Inc.

Recombinant Human Bone Morphogenetic Protein-2 Delivered in an Injectable Calcium Phosphate Paste Accelerates Osteotomy-Site Healing in a Nonhuman Primate Model

Howard J. Seeherman, PhD, VMD1, Mary Bouxsein, PhD1, Hyun Kim, PhD1, Rebecca Li, PhD1, X. Jian Li, MD1, Maria Aiolova, PhD2 and John M. Wozney, PhD1

1 Women's Health and Bone, Wyeth Discovery Research, 200 Cambridge Park Drive, Cambridge, MA 02140. E-mail address for H.J. Seeherman: hseeherman{at}wyeth.com
2 ETEX, University Park at MIT, 350 Massachusetts Avenue, Cambridge, MA 02139

Investigation performed at Women's Health and Bone, Wyeth Discovery Research, Cambridge, Massachusetts

The authors did not receive grants or outside funding in support of their research or preparation of this manuscript. One or more of the authors received payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity. (H.J. Seeherman, M. Bouxsein, H. Kim, R. Li, X.J. Li, and J. M. Wozney are employees of Wyeth. M. Aiolova is an employee of ETEX. The {alpha}-BSM was provided by ETEX.) No commercial entity paid or directed, or agreed to pay or direct, any benefits to any research fund, foundation, educational institution, or other charitable or nonprofit organization with which the authors are affiliated or associated.

Background: In recent clinical trials demonstrating the efficacy of recombinant human bone morphogenetic protein-2 (rhBMP-2) for the acceleration of bone-healing, investigators used carriers requiring open surgery for administration. In this study, we used a nonhuman primate fibular osteotomy model to evaluate injectable rhBMP-2/carrier formulations that can be administered in closed fractures.

Methods: The fibular osteotomy model was first characterized by evaluating surgically harvested fibular segments containing untreated osteotomy sites (controls) from seventy adult male Cynomolgus monkeys at eight weeks (twenty-four monkeys), ten weeks (thirty-four), twelve weeks (six), and fourteen weeks (six). Fibular segments, from twenty-four animals, in which an osteotomy had not been performed served as normal controls (intact). The contralateral limb of twenty-four of the animals was then used to evaluate the effect of rhBMP-2 administered, three hours after the osteotomy, in eight carrier formulations (buffer, calcium phosphate paste, and hyaluronan gel, hyaluronan paste, and gelatin foam formulated with and without tricalcium phosphate granules). Each carrier was used in three monkeys. At ten weeks, the fibulae with the treated osteotomy sites were harvested and were compared with the contralateral, untreated osteotomized fibulae (paired control). The most promising carrier, calcium phosphate paste (alpha bone substitute material, or {alpha}-BSM), was then evaluated in eleven additional animals. The outcomes included the findings on radiographs made weekly until the time of fibular harvest, the callus area, the biomechanical properties, and the histologic findings.

Results: Radiographic and histologic studies confirmed complete bridging of the control osteotomy sites in most animals by fourteen weeks. The mean torsional stiffness and maximum torque of the control osteotomy sites were 42.7% and 53.7%, 55.2% and 60.4%, 66.7% and 66.4% of the mean torsional stiffness and maximum torque of the intact fibulae at eight, ten, and twelve weeks, respectively, but they were not substantially different from the mean torsional stiffness and maximum torque of the intact fibulae at fourteen weeks (82.3% and 79.8%). In the carrier screening study, outcome measures of healing were more consistently enhanced in the rhBMP-2/{alpha}-BSM-treated osteotomy sites. In the confirmatory study, the mean callus area, torsional stiffness, and maximum torque were 86%, 72%, and 68% greater in the rhBMP-2/{alpha}-BSM-treated osteotomy sites than in the paired-control osteotomy sites at ten weeks (p < 0.001). The torsional stiffness and maximum torque in the rhBMP-2/{alpha}-BSM-treated osteotomy sites were equal to those in the intact fibulae, whereas those parameters in the paired-control osteotomy sites were only 55% and 58%, respectively, of the torsional stiffness and maximum torque of the intact fibulae. Histologic analysis confirmed complete osseous bridging of the rhBMP-2/{alpha}-BSM-treated osteotomy sites but incomplete bridging of the paired-control osteotomy sites at ten weeks.

Conclusions: A single percutaneous injection of rhBMP-2/{alpha}-BSM accelerates the healing of fibular osteotomy sites in nonhuman primates by approximately 40% compared with the healing of untreated osteotomy sites.

Clinical Relevance: These results provide a rationale for evaluating rhBMP-2/{alpha}-BSM as a means with which to accelerate healing in humans with closed fractures.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Facebook Facebook   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JBJSHome page
H. J. Seeherman, X. J. Li, M. L. Bouxsein, and J. M. Wozney
rhBMP-2 Induces Transient Bone Resorption Followed by Bone Formation in a Nonhuman Primate Core-Defect Model
J. Bone Joint Surg. Am., February 1, 2010; 92(2): 411 - 426.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
H. J. Seeherman, K. Azari, S. Bidic, L. Rogers, X. J. Li, J. O. Hollinger, and J. M. Wozney
rhBMP-2 Delivered in a Calcium Phosphate Cement Accelerates Bridging of Critical-Sized Defects in Rabbit Radii
J. Bone Joint Surg. Am., July 1, 2006; 88(7): 1553 - 1565.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
H. Seeherman, R. Li, M. Bouxsein, H. Kim, X. J. Li, E. A. Smith-Adaline, M. Aiolova, and J. M. Wozney
rhBMP-2/Calcium Phosphate Matrix Accelerates Osteotomy-Site Healing in a Nonhuman Primate Model at Multiple Treatment Times and Concentrations
J. Bone Joint Surg. Am., January 1, 2006; 88(1): 144 - 160.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
S. A. Rodeo, C. Hidaka, and S. A. Maher
What's New in Orthopaedic Research
J. Bone Joint Surg. Am., October 1, 2005; 87(10): 2356 - 2365.
[Full Text] [PDF]